Loading
Encision Inc Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest, by Shepard Brandon Jason, was filed 21 Aug 2025.
Insider Decl.
161
Thresholds
n/a
Buy Volume
€3M
117 ops. · all time
Sell Volume
€104,284
9 ops. · all time
Who traded when
BuySaleBrandon Jason Shepard1 buy
Cmed Partners LLLP1 buy
Gregory J. Trudel1 buy
Robert H. Fries1 buy
Since the insiders bought
- -80.8%Entry US$0.21 · Close at T+365 US$0.04
- -80.8%Entry US$0.21 · Close at T+365 US$0.04
- -80.8%Entry US$0.21 · Close at T+365 US$0.04
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2025FY ended March 2025 · cache
US$0.01
Analyst consensus
Income statement
RevenueUS$6.6M
Gross profitUS$3.5M54% margin
EBITDA-US$95.1k-1% margin
Net income-US$220.2k-6.0% margin
Valuation
P/Book0.1x
Beta-7.82
Balance sheet & cash
Total debtUS$1.3M
Free Cash Flow-US$135k
Debt / Equity82%
Profitability & ownership
ROE-21.4%
ROA-5.3%
% insiders61.4%
% institutions5.5%
Last declaration on 21 August 2025
Declarations161 total
1,000,000 shares@ US$0.10100.0% of flowCommon StockSEC:0002039195-25-000003:0
Canonical exit: 17 Nov 2025 (T+90)
1,000,000 shares@ US$0.1045.5% of flowCommon StockSEC:0001594965-25-000002:0
Canonical exit: 17 Nov 2025 (T+90)
750,000 shares@ US$0.1073.0% of flowCommon StockSEC:0001263239-25-000002:0
Canonical exit: 17 Nov 2025 (T+90)
2,000,000 shares@ US$0.10100.0% of flowCommon StockSEC:0001079973-25-001373:0
Canonical exit: 17 Nov 2025 (T+90)
5,000 shares@ US$0.3514.3% of flowCommon StockSEC:0000930775-24-000008:0
5,000 shares@ US$0.355.7% of flowCommon StockSEC:0000930775-24-000010:0
5,000 shares@ US$0.350.9% of flowCommon StockSEC:0000930775-24-000009:0
35,000 shares@ US$0.36813.2% of flowCommon StockSEC:0000930775-24-000002:0
Canonical exit: 27 Nov 2024 (T+90)
3,300 shares@ US$0.320.5% of flowCommon StockSEC:0000930775-24-000001:0
Canonical exit: 18 Nov 2024 (T+90)
10,286 shares@ US$0.3455.3% of flowCommon StockSEC:0001555569-24-000007:0
11,259 shares@ US$0.75Common StockSEC:0001555569-24-000004:1
11,259 shares@ US$0.75Common stockSEC:0001555569-24-000006:1
13,435 shares@ US$0.75Common stockSEC:0001555569-24-000003:1
125,627 shares@ US$0.75Common StockSEC:0001555569-24-000005:1
20,000 shares@ US$0.3823.9% of flowCommon StockSEC:0001555569-24-000006:0
19,667 shares@ US$0.4467.0% of flowCommon stockSEC:0001555569-24-000003:0
200,000 shares@ US$0.33532.8% of flowCommon stockSEC:0001555569-24-000005:0
20,000 shares@ US$0.33Common stockSEC:0001555569-24-000002:1
17,715 shares@ US$0.46Common StockSEC:0001555569-24-000002:2
16,315 shares@ US$0.46Common stockSEC:0001555569-24-000002:3
20,000 shares@ US$0.3859.5% of flowCommon stockSEC:0001555569-24-000002:0
6,069 shares@ US$0.46Common StockSEC:0001555569-22-000014:1
Canonical exit: 16 Feb 2023 (T+90)
18,931 shares@ US$0.449.1% of flowCommon StockSEC:0001555569-22-000014:0
Canonical exit: 14 Feb 2023 (T+90)
10,000 shares@ US$0.4615.5% of flowCommon StockSEC:0001555569-22-000005:0
Canonical exit: 7 Feb 2023 (T+90)
40,000 shares@ US$0.4154.8% of flowCommon StockSEC:0001555569-22-000004:0
Canonical exit: 6 Oct 2022 (T+90)
25 of 161 declarations
About Encision Inc
Encision Inc's insiders buy: the record holds 49 purchases (13 with an amount) worth EUR 459,908, with a median of EUR 9,075, and no sale. On August 19, 2025, 4 filers bought for EUR 407,987, including Cmed Partners LLLP for EUR 171,784, Brandon Jason Shepard (VP of Finance) and Gregory J. Trudel (CEO) for EUR 85,892 each. In all, 6 purchase filings are flagged as part of a cluster.
Robert H. Fries (Director) files the most, 26, of which 25 purchases, ahead of Gregory J. Trudel (20, of which 13 purchases), Brian J. Jackman (VP Marketing, 7) and Peter D. Geary (7, of which 3 purchases). Insiders hold 61.4% of the capital.
Read moreShow less
The 76 filings from 10 insiders were published from February 17, 2016 to August 21, 2025, with 11 grants, 8 option exercises and 8 filings of another kind. Annual volume runs from 2 filings in 2018 to 17 in 2024 and 13 in 2019, and none was published in the last twelve months. The median delay is 4 days.
For 12 purchases with a stored 90-day result, the median is 9.3% and 58% are positive: stored past results, not a forecast. This US company belongs to the healthcare and pharma sector.
